PDGFR-α
KRAS, EGFR, PDGFR-α, KIT and COX-2 status in carcinoma showing thymus-like elements (CASTLE)
... 3, PDGFR- α , c-KIT, FLT3, colony stimulating factor-1 (CSF1) and the RET receptor, is more effective than therapeutic regimes using single-target mo- lecular therapies like Gefitinib, even though there are ...
7
Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics
... oncogenic PDGFR α mutant proteins To evaluate whether the observed non-conventional ac- tivation of STAT factors by the oncogenic mutants is linked to their mislocalisation, we investigated the sig- nalling ...
21
KIT exon 11 and PDGFRA exon 18 gene mutations in gastric GIST: proposal of a short panel for predicting therapeutic response
... whereas PDGFR Α gene mutations in exon 18 (D842V) are resistant to the same drug, the aim of this study is to focus on these two molecular targets as a short alternative panel for predicting therapeutic ...
9
Selective deletion of hepatocyte platelet-derived growth factor receptor α and development of liver fibrosis in mice
... Upon liver injury, HSCs are activated by cytokines, including platelet-derived growth factors (PDGFs), which are potent mitogens [9, 10]. PDGFs exist as five isoforms: PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD. The ...
11
Involvement of <em>c-KIT</em> mutation in the development of gastrointestinal stromal tumors through proliferation promotion and apoptosis inhibition
... mately 90% of GIST cases have gain-of-function mutations of either Kit or platelet- derived growth factor receptor, alpha polypeptide (PDGFR α ) tyrosine kinases, and such mutations may[r] ...
7
PDGF/PDGFR effects in osteosarcoma and the “add-on” strategy
... PDGF-C, and PDGF-D, and two receptors, PDGFR-α and PDGFR-β. All PDGFs function as disulfide-linked homodimers, but only PDGF-A and -B can form func- tional heterodimers. Before binding to the protein ...
9
Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
... Pericytes surround the endothelial cells of small vessels and are embedded in their basement membrane. Through interactions with endothelial cells, pericytes are involved in vessel function and maturation, which includes ...
11
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
... medium when the cells are grown in vitro, supporting an auto- crine role for PDGF signaling in these cells. Olaratumab has antitumor activity against a xenograft model of SK-LMS-1 in nude mice at doses between 6 and 20 ...
6
Platelet-derived growth factor regulates the secretion of extracellular vesicles by adipose mesenchymal stem cells and enhances their angiogenic potential
... HMEC: Human microvascular endothelial cells; PDGF: Platelet-derived growth factor; PDGFR α / β : Platelet-derived growth factor receptor alpha/beta; VEGF: Vascular endothelial growth fac[r] ...
12
Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms
... regulates PDGFR protein levels. Given the observed changes in PDGFR-β at the transcription lev- el, we sought to confirm changes in PDGFR-β at the protein ...only PDGFR-β, but also other ...
19
Targeting invadopodia to block breast cancer metastasis
... We were therefore interested in the mechanism by which Twist1 was both necessary and sufficient for invadopodia formation. None of the structural or enzymatic proteins found in invadopodia that we investigated, including ...
7
Overexpression of platelet derived growth factor receptor α in breast cancer is associated with tumour progression
... between PDGFR-α expression and HER-2 expression is quite interesting, and probably proves the previous results about the correlation of PDGFR- α pathway with ...expressed PDGFR-α ...
8
Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy
... Abstract: Soft-tissue sarcoma (STS) is a heterogeneous group of tumors that arise from mesenchymal tissue. The prognosis of metastatic STS is poor with a life expectancy of 12–18 months. The mainstay of treatment is ...
9
Huber, Katharina (2005): Ursprung, Entwicklung und Differenzierung von Oligodendrozyten. Dissertation, LMU München: Tierärztliche Fakultät
... In Studien zur Erforschung der Ursprungsorte der Oligodendrozyten fand häufig der α-Rezeptor für den platelet derived growth factor (PDGFR-α) als Marker Verwendung, da dieser sich als[r] ...
124
TARGETING ONCOGENIC KINASE SIGNALING WITH SMALL MOLECULE KINASE INHIBITOR IMATINIB
... After the development of imatinib by rational drug design, it was tested several times in preclinical models. It was found that submicromolar concentrations of this compound inhibited v-Abl, PDGF receptor, and KIT ...
10
Autocrine PDGFR signaling promotes mammary cancer metastasis
... autocrine PDGFR signaling with oncogenic Ras hyperactivates PI3K and is required for survival during ...Autocrine PDGFR signaling also contributes to maintenance of EMT, possibly through activation of STAT1 ...
11
Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells
... Abstract: Melanoma is the deadliest form of skin cancer, and BRAFV600E is a driver mutation that promotes melanoma growth and survival. PLX4032 is the first effective compound in clini- cal use for the treatment of ...
9
Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors
... A number of agents capable of inhibiting PDGFR sig- naling have been developed including Sunitinib malate (Sutent), BAY 73–4506 (Regorafenib) and Imatinib mesy- late (Gleevec). Sunitinib malate inhibits PDGFRβ, ...
9
Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells
... Among the family of receptor tyrosine kinases (RTKs), platelet-derived growth factor receptor (PDGFR) has attracted increasing attention as a potential target of anti-tumor therapy in colorectal cancer (CRC). To ...
13
COMPARATIVE DOCKING AND MUTATIONAL STUDIES CKIT AND PDGFR A INHIBITORS IN GASTROINTESTINAL STROMAL TUMORS
... sarcoma found in the digestive system, most often in the wall of the stomach. Some GISTs are not cancerous (they are benign.) But they can become cancerous if not treated. Mutually exclusive KIT and PDGFRA mutations are ...
12